Atlas Trials

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Clinical trial NCT05989828 · RECRUITING

Trial details

NCT number
NCT05989828
Sponsor
University of Southern California
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2024-12-17
Primary completion
2027-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.